Search company, investor...


Founded Year


About KeraCure

KeraCure is developing wound healing therapies through development of a platform technology that will simplify usage of cell-based therapies.

Headquarters Location

101 North Wacker Drive Suite 610

Chicago, Illinois, 60606,

United States

Missing: KeraCure's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KeraCure's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

KeraCure Patents

KeraCure has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Cell biology, Transcription factors, Biotechnology, Developmental biology, Stem cells


Application Date


Grant Date



Related Topics

Cell biology, Transcription factors, Biotechnology, Developmental biology, Stem cells



KeraCure Frequently Asked Questions (FAQ)

  • When was KeraCure founded?

    KeraCure was founded in 1999.

  • Where is KeraCure's headquarters?

    KeraCure's headquarters is located at 101 North Wacker Drive, Chicago.

  • Who are KeraCure's competitors?

    Competitors of KeraCure include OcuNexus Therapeutics, Adhezion Biomedical, Regentis Biomaterials, Biovertis, Arteriocyte and 12 more.

Compare KeraCure to Competitors

Adhezion Biomedical

Adhezion Biomedical is a medical device company focused on the development and commercialization of cyanoacrylate-based surgical, wound management and infection prevention technologies for use in professional and consumer healthcare settings.


Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

Type IV Technologies

Type IV Technologies, L.L.C. ("Type IV"), is a company formed in 2002 to develop a new therapy that will change the current standard of care for people with warts. This new therapy, immunotherapy for Human Papillomavirus (HPV) infections, involves using FDA-approved skin test antigens both by themselves and in combination to induce an immunologic response that rids the body of warts.

DermAvance Pharmaceuticals

DermAvance Pharmaceuticals, a pharmaceutical company engaged in advanced technology applications for skin health and cosmetic dermatology, announced the acquisition of the North American rights for the Hyalogy Total Skin Care Line from Forlle'd in Japan.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.